On the stock market since 1991, it operates in the world of health and science. It has 207 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Revenue is spread across several lines; no single product carries the company.
No real growth. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 39% a year on average.
Sales run at $8.6M a year. A small number, but proof the product has real buyers.
The average analyst price target is $1.50 — 331% above today’s price.
A loss of $78.4M against $8.6M in annual sales.
The stock sits at $0.35. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, ASXC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ASXC is a high-risk stock — not yet profitable, and its future rides on its product catching on.